Rapid Industrialization to Boost Cancer Gene Therapy Market Growth at a CAGR of 32.4% from 2017 to 2023

Rapid Industrialization to Boost Cancer Gene Therapy Market Growth at a CAGR of 32.4% from 2017 to 2023

Cancer Gene Therapy Marke: Drivers and Restraints by 2023
Cancer Gene Therapy Market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023. This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.Market estimations are based on comprehensive analysis of the key developments in the industry.

Increased prevalence of cancer, and rise in global geriatric population, and high growth potential in the untappedmarkets of developing countries are expected to boost the growth of the global cancer gene therapy market 

Allied Market Research recently published a report, titled, “Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer): Global Opportunity Analysis and Industry Forecast, 2017-2023.” The report offers an in-depth analysis of the market dynamics, top winning strategies, key market segments, top investment pockets, and competitive landscape. According to the report, the global cancer gene therapy market was valued at $385.8 million and is expected to reach $2,082.5 million by 2023, registering a CAGR of 32.4% through 2023.

Download Sample: https://www.alliedmarketresearch.com/request-sample/2605

Cancer gene therapy is an approach for the cancer treatment, where genetically engineered vectors such as viruses are used to transfer or replace a mutated gene (that is causing cancer) with a heathy gene. This technique can be used for both the prevention and treatment of disease. The most commonly used techniques for the treatment using cancer gene therapy includes oncolytic virotherapy, gene transfer, and gene-induced immunotherapy.

The rise in prevalence of cancer, ethical acceptance of gene therapy for cancer treatment, and the advancement in this field drive the market growth. In addition, benefits of cancer gene therapy over conventional cancer therapies, increase in government support, and rise in biotechnological funding that encourage the R&D activities for cancer gene therapy fuel the growth of the cancer gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to restrain the market growth.

Among the therapy segment, oncolytic virotherapy segment is the largest contributor toward the market growth and gene transfer therapy segment is anticipated to be a lucrative market due to the positive results for these therapies during the preclinical and clinical trials for the treatment of cancer.

In 2016, North America accounted for maximum contribution to the total revenue generated, owing to the high prevalence rate of cancer, presence of high disposable income, and high funding for R&D activities associated with cancer gene therapy. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to rise in incidence rate of cancer, increase in government initiative to improve healthcare infrastructure, and rise in healthcare expenditure.

Key Findings of the Cancer Gene Therapy Market:

  • Gene tranfer segment is projected to grow at the highest rate during the analysis period.
  • Oncolytic virotherapy segment generated the highest revenue, and is expected to continue its dominance in the future.
  • North America dominated the global cancer gene therapy market, and is projected to continue its dominance in future.
  • China is expected to grow highest in the Asia-Pacific region.
  • Asia-Pacific is expected to be the fastest growing segment during the forecast period.


For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/2605


Leading Key Players:-

The key companies profiled in the report include Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals.

Similar Reports:

Oncology/Cancer Drugs Market : Global Opportunity Analysis and Industry Forecast, 2018 – 2025

Gynecological Cancer Drugs Market – Global Opportunity Analysis and Industry Forecast, 2017-2023


About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Media Contact
Company Name: Allied Market Research
Contact Person: David Correa
Email: Send Email
Phone: +1-800-792-5285
Address:5933 NE Win Sivers Drive #205
City: Portland
State: OR 97220
Country: United States
Website: www.alliedmarketresearch.com/cancer-gene-therapy-market